DAVID GRAHAM to Cost-Benefit Analysis
This is a "connection" page, showing publications DAVID GRAHAM has written about Cost-Benefit Analysis.
Connection Strength
0.465
-
The cost-effectiveness of radiofrequency ablation for treating patients with gastric antral vascular ectasia refractory to first line endoscopic therapy. Curr Med Res Opin. 2020 06; 36(6):977-983.
Score: 0.142
-
Helicobacter pylori infection in India from a western perspective. Indian J Med Res. 2012 Oct; 136(4):549-62.
Score: 0.084
-
Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-36.
Score: 0.060
-
The time to eradicate gastric cancer is now. Gut. 2005 Jun; 54(6):735-8.
Score: 0.051
-
Is the use of COX-2 inhibitors in gastroenterology cost-effective? Nat Clin Pract Gastroenterol Hepatol. 2004 Dec; 1(2):60-1.
Score: 0.049
-
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 12; 69(12):2093-2112.
Score: 0.037
-
A cost-effectiveness analysis of endoscopic eradication therapy for management of dysplasia arising in patients with Barrett's oesophagus in the United Kingdom. Curr Med Res Opin. 2019 05; 35(5):805-815.
Score: 0.032
-
Prevention of complicated ulcer disease among chronic users of nonsteroidal anti-inflammatory drugs: the use of a nomogram in cost-effectiveness analysis. Arch Intern Med. 2002 Oct 14; 162(18):2105-10.
Score: 0.011